West Pharmaceutical Services, Inc., a provider of solutions for injectable drug administration, opened a new state-of-the-art research and development lab in Radnor, PA, that will house over 35 employees.

The investment is in addition to West’s $400 million in global expansion efforts, and will support the company’s capability enhancements in chemistry, material sciences, and biology, while meeting the growing needs of its products and services to support complex sensitive molecules and the changing regulatory environment.

“As the scientific industry gets increasingly more sophisticated with new technology– improving our understanding of our patients will come more sharply into focus. West’s new research and development lab allows us to bring our one hundred years of scientific and technical expertise together so we can continue to define what is possible in improving patients’ health.” said Anya Harry, vice president of R&D and chief medical officer/applied research. “The lab is an essential part of West’s overall growth to better support our customers, our growing partnerships, and find new ways to conduct our research.”

West’s R&D lab at Radnor is part of its strategic focus on delivery of advanced therapy and new therapeutic experiences across containment and systems.

West innovators at this site will work side-by-side creating novel technologies to enhance products that solve challenges in the safe and thoughtful delivery of life-saving medicines.

“West is committed to growing its business through strategic R&D investments to drive innovation,” said Scott Young, vice president venture & external collaboration, research & development at West. “The R&D lab at Radnor will enhance our collaborations with existing and future customers to innovate and accelerate their drug delivery strategies.”